Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07058428Phase 3Recruiting

FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma

Role: lead

NCT06849180Recruiting

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Role: collaborator

NCT01761409Unknown

Epidemiological Analysis on Endometrial Cancer in Guangdong Province of China

Role: collaborator

All 3 trials loaded